Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity

• Published in: Frontiers in physiology Vol. 9; p. 1125
• Main Authors: Zhu, Huijuan, Liu, Meijuan, Zhang, Nianrong, Pan, Hui, Lin, Guole, Li, Naishi, Wang, Linjie, Yang, Hongbo, Yan, Kemin, Gong, Fengying
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 10.09.2018
• Subjects: activating transcription factor 3; adipose tissue; colorectal cancer; fibronectin type III domain-containing protein 5/irisin; obesity; Physiology; adipose tissue; colorectal cancer; activating transcription factor 3; obesity; fibronectin type III domain-containing protein 5/irisin
• DOI: 10.3389/fphys.2018.01125
• ISSN: 1664-042X

To explore the activating transcription factor 3 (ATF3) and fibronectin type III domain-containing protein 5 (FNDC5)/irisin protein levels in serum and mRNA levels in subcutaneous and visceral white adipose tissue (sWAT and vWAT) in normal-weight (NW) and overweight/obese (OW/OB) patients with colorectal cancer (CRC). 76 CRC patients and 40 healthy controls were recruited. Serum ATF3 and irisin levels were detected by using ELISA kits, and the mRNA expression levels in sWAT and vWAT were measured by performing RT-qPCR. The serum ATF3 levels were greater by 37.2%, whereas the irisin levels were lower by 23.3% in NW+CRC patients compared with those in healthy controls. CRC was independently associated with both ATF3 and irisin levels. The probability of CRC greater by 22.3-fold in individuals with high ATF3 levels compared with those with low ATF3 levels, whereas the risk of CRC in subjects with high irisin levels was lower by 78.0% compared to the risk in those with low irisin levels after adjustment for age, gender, BMI, and other biochemical parameters. Serum ATF3 and irisin could differentiate CRC patients from controls with receiver operating characteristic (ROC) curve areas of 0.745 (95% CI, 0.655-0.823) and 0.656 (95% CI, 0.561-0.743), respectively. The combination of ATF3 and irisin exhibited improved diagnosis value accuracy with ROC curve areas of 0.796 (95% CI, 0.710-0.866) as well as 72.6% sensitivity and 80.0% specificity. Increased ATF3 and reduced irisin levels were observed in sera from CRC patients. Individuals with high ATF3 and low irisin levels were more likely to have CRC. ATF3 and irisin represent potential diagnostic biomarkers for CRC patients.